J. Pu

Association of nuclear factor κB expression with a poor outcome in nasopharyngeal carcinoma

Y. Yang, Jin Wang, G. Xie, 2011, Medical oncology.

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.

Lei Zheng, A. Bullock, P. Jiang, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overexpression of Y-box binding protein-1 in cervical cancer and its association with the pathological response rate to chemoradiotherapy

G. Feng, T. Dai, J. Wang, 2012, Medical Oncology.

Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study.

Amber C. Donahue, J. Desai, Zhou Zhu, 2021 .

Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).

A. Bullock, X. Wu, P. Jiang, 2017 .

Hyaluronan assessment in tumor microenvironment using new affinity histochemistry assay and scoring method.

X. Wu, P. Jiang, Junming Zhu, 2017 .

Novel mutations in one allele in a Chinese family with neurofibromatosis type 1: Including a complex insertion–deletion mutation

Lei Shi, Xiuli Wang, Yunfeng Zhang, 2016, The Journal of dermatology.

LBA74 Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)

T. Powles, J. Bellmunt, P. Grivas, 2022, Annals of Oncology.

763PRandomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)

A. Bullock, P. Jiang, S. Hingorani, 2017 .

Final analysis of stage 1 data from a randomized phase II study of PEGPH20 plus nab-Paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients (pts), utilizing Ventana companion diagnostic assay.

A. Bullock, X. Wu, P. Jiang, 2016 .

316O Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study

E. Van Cutsem, R. Yaeger, S. Kopetz, 2022, Annals of Oncology.